Prima BioMed (NASDAQ:IMMP) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Prima BioMed Ltd (NASDAQ:IMMP)’s stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.44 and traded as low as $0.3925. Prima BioMed shares last traded at $0.4169, with a volume of 660,523 shares changing hands.

Analyst Ratings Changes

A number of brokerages have commented on IMMP. Robert W. Baird lowered shares of Prima BioMed from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $7.00 to $1.00 in a report on Friday, March 13th. Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Citizens Jmp cut shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research note on Friday, March 13th. Finally, Maxim Group raised shares of Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.50.

Prima BioMed Trading Up 2.3%

The business’s 50-day simple moving average is $0.44 and its 200-day simple moving average is $1.55.

Hedge Funds Weigh In On Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC raised its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company’s stock.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.